Clinical trial · Observational
Predictive MRI Metrics for Tumor Aggressiveness in Papillary Thyroid Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Magnetic resonance imaging (MRI) is a diagnostic technique that takes pictures of organs of the body. It uses magnetic fields and radio waves that cannot be felt. Perfusion MRI uses faster imaging. It also includes a contrast material that is given by vein. This makes specific organs, blood vessels, or tumors easier to see. Diffusion MRI lets us measure the motion of water in the tumor. Perfusion and diffusion MRI give extra information which is not available with the regular MRI. A regular MRI only shows pictures of the tumor. Thyroid MRI scans are not part of the current standard of care. The purpose of this study is to see if new MRI methods can give us more information about the tumor.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Papillary Thyroid Cancer | Thyroid Gland Papillary Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| diffusion weighted (DW) MRI | Procedure | — | UNRESOLVED |
| dynamic contrast agent (DCE) MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Surgical patients
- description
- The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study prior to surgery. The maximum time interval allowed between the MRI study and surgery will be six months.
- interventionNames
- Procedure: diffusion weighted (DW) MRI
- Procedure: dynamic contrast agent (DCE) MRI
- label
- surveillance management patients
- description
- The patients will undergo DW-MRI and (if patient is eligible and agrees) DCE-MRI study while being on active surveillance.These patients can also receive the same DW and DCE MRI as a followup a year after the first.
- interventionNames
- Procedure: diffusion weighted (DW) MRI
- Procedure: dynamic contrast agent (DCE) MRI
Primary outcomes (1)
- measure
- feasibility of MRI biomarkers
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Biopsy proven Papillary Thyroid Cancer (regardless of genotype and including all subtypes such as follicular or mixed papillary follicular) or suspicious for Thyroid Cancer * Thyroidectomy or lobectomy planned as definitive treatment for Thyroid Cancer or patients on active surveillance management approach * Age ≥18 years Exclusion Criteria: * Patient would require anesthesia for the study * Patients who are claustrophobic Patients with tumor size greater than 5 cm in diameter as measured at imaging (ultrasonography or MRI) before treatment * Patients who have presence of a known contraindication to MRI * Pacemaker * Aneurysmal clips * Metal implants in field of view * Pregnant * Age and mental status wherein he/she is unable to cooperate for MRI study Patients who have presence of a known contraindication to DCE-MRI may not participate in that portion of the study * Known reaction to Gd-DTPA, contrast agent * Chronic kidney disease * nursing women
References
Publications (0)
Data not yet available